Introduction
Part B drug collections can represent a substantial share of revenue for office-based oncology practices. When a billing company charges a percentage of all collections, high-value drug receipts can materially affect the total fee. Infusion administration claims may generate less revenue per claim while requiring detailed review of time, sequencing, documentation and payer decisions. A meaningful cost comparison should therefore examine drug and administration revenue separately.
Here is how to think about the real cost, the infusion billing issues that drive recovery, and the metrics that actually matter for oncology.
The Cost Framework That Actually Applies to Oncology
Cost to collect remains useful in oncology, but it should be supplemented with separate views of drug and administration revenue. Otherwise, high-value drug collections may obscure differences in workload and performance.
If you are evaluating an outsourced model, the first question is not "what is your percentage?" The first question is "what does your percentage apply to?"
Some vendors charge their fee on all collections, including drugs. Others will carve out drug receipts and charge a lower rate on professional and administration services. In this illustrative example, the difference between 4% of $30 million and a tiered arrangement charging 4% of $8 million plus 1% of $22 million is $660,000 a year. Same vendor, same work, completely different cost.
Get this in writing before you sign anything. Ask specifically about:
- Whether drug receipts are included in the fee base
- How patient payments collected at the front desk are treated
- Whether old A/R recovery carries a separate contingency fee
- How refunds and recoupments affect the fee calculation
If you are evaluating your in-house model, the cost of an in-house model is not limited to salaries. It also includes benefits, technology, management, staffing coverage and validated collectible revenue at risk from unresolved denials or underpayments.
A Practical Way to Measure This: Pull infusion administration claims from the last six months. Separate claims paid correctly on first adjudication from denials, underpayments and unresolved claims. After removing contractual adjustments, duplicates and amounts that are not reasonably collectible, calculate the validated balance at risk. This is not guaranteed recovery, but it provides a more useful figure for comparing additional staffing or vendor costs.
The Infusion Billing Issues That Cost You Money
Here are three infusion billing problems common in cancer centers that should factor into your staffing decision.
- Drug waste reporting is a compliance issue and a revenue issue. Medicare has required the JW modifier on applicable claims involving discarded amounts since 2017. The JZ modifier became mandatory on applicable claims beginning July 1, 2023, when no amount was discarded from a separately payable Part B drug supplied in a single-dose container or single-use package. The CMS JW/JZ modifier guidance is specific about the documentation required, and CMS states that applicable claims missing the correct JW or JZ modifier may be subject to provider audits and may be returned unprocessed. If your billing team is not reconciling the medication administration record against the pharmacy dispensing record and the claim for each applicable drug claim, you may leave allowable payment unreported or increase the risk of billing errors and recoupment. It is a volume task. Apply this control to every applicable claim. Whether your in-house team has the capacity to do it or you have a vendor doing it is a legitimate staffing question.
- Infusion time documentation is essential when time determines the administration code. Medicare contractor guidance, including Palmetto GBA Article A53778, may expect documentation of actual start and stop times or sufficient information to calculate the infusion duration. When a patient receives multiple drugs sequentially, coding depends on the drug, route, service hierarchy, infusion duration, sequencing, concurrency and access sites. The bundling rules are laid out in the 2026 Medicare NCCI Policy Manual, Chapter XI and are not intuitive. A common mistake is billing two initial infusion codes on the same visit when generally only one is permitted unless medically necessary administrations occur through separate intravenous access sites, or billing hydration as a separate service when it was running concurrently with chemotherapy. Pre-submission review of the infusion record against the claim can help prevent these denials. If your in-house team is processing claims at high volume without a dedicated review step for complex infusion encounters, this is where errors tend to accumulate. Organizations should follow the documentation requirements applicable to their payer, setting, and Medicare jurisdiction.
- Prior authorization for high-cost drugs is a moving target. Payer oncology drug policies and authorization requirements can change. An authorization that was valid for cycle one may not cover a dose adjustment in cycle three. The CMS prior authorization final rule (CMS-0057-F) sets new timeframe requirements for certain payers starting in 2026, but those decision-timeframe requirements exclude drugs and do not apply to Qualified Health Plan issuers on federally facilitated exchanges. Your team needs to track authorization status at the regimen level, not just the patient level, and flag when a treatment change triggers a new authorization requirement.
What You Can and Cannot Benchmark
The HFMA MAP Keys provide standard definitions for metrics such as cost to collect and net days in A/R and you should use those definitions so that your numbers actually mean something. The target numbers however vary so dramatically by practice size, payer mix, drug formulary and site of service that a generic benchmark may be misleading without proper segmentation and context. What you can benchmark is your own performance over time. Here are the metrics that actually matter in oncology:
- Infusion denial rate by reason. Separate authorization denials from coding denials from documentation denials. Rising authorization or coding denials may indicate problems with verification, documentation, payer rules, training or claim review.
- Drug claim acceptance rate on first submission. Establish a baseline for first-submission drug-claim acceptance and investigate material changes by payer, drug, location, and rejection reason.
- Administration underpayment rate. Compare what the payer paid against the contracted allowance for your top 20 infusion administration codes. Administration underpayments can remain undetected when paid claims are not compared with contracted allowances. Across hundreds of infusions per month, they add up.
- Days to resolve infusion denials. Track how long it takes from the denial date to the resolution date for infusion claims specifically. If this number is growing, your team may be falling behind on complex infusion receivables.
- JW/JZ compliance rate. Audit a sample of applicable Medicare Part B single-dose drug claims each month. Check whether the modifier is present when required and whether the discarded amount matches the documentation. This is a compliance metric, not just a revenue metric.
Making the Decision
The right model for your cancer center depends on three things: the complexity of your payer mix, the volume of infusion services you provide, and whether your current team has the bandwidth to work complex claims while processing high-volume drug billing.
- In-house makes sense when your billing team has genuine oncology coding expertise, your denial rate on infusion claims is low and stable, your drug waste reporting is compliant, and your leadership can validate the numbers in your monthly reports.
- Outsourcing makes sense when you have a documented backlog of unresolved infusion denials, your team is spending most of their time on drug claims and not getting to the complex work, your payer mix includes multiple Medicare Advantage plans with different oncology drug policies, or you are opening new locations and cannot recruit oncology-experienced billers fast enough.
- A hybrid model makes sense when your drug billing runs smoothly but your infusion denial recovery and administration underpayment work are falling behind. In that case, outsourcing the denial and A/R recovery function while keeping front-end billing in-house can give you the best of both models without the full cost of a percentage-based contract on all collections.
Whatever you decide, separate drug revenue from administration revenue in your reporting. Track infusion-specific metrics alongside your overall RCM numbers. And make sure whoever handles your billing, internal or external, can demonstrate actual oncology expertise rather than general medical billing experience with a cancer center on their client list.
Frequently Asked Questions
Should I negotiate a different fee rate for drug claims vs. administration claims?
Yes, if your vendor charges a percentage of total collections. Drug and administration claims generate different collection amounts and can require different types of billing work. A flat percentage across both may create a mismatch between the vendor's fee and the work required. Model a tiered rate or drug carve-out against the complete service scope before deciding.
How do I know if my in-house team is missing infusion revenue?
Take your last 90 days of infusion administration claims and compare the paid amount against the contracted allowance for each payer. If you see a pattern of payments that fall below the contracted rate and nobody is working those underpayments, that is your gap. If the team prioritizes denials, smaller underpayments may remain unresolved unless they have a separate work queue.
Does outsourcing drug billing make sense separately from infusion billing?
It can. Some cancer centers keep drug billing in-house when it already has an established internal workflow, then outsource infusion denial recovery and administration underpayment work to a specialty vendor. This hybrid approach avoids paying a percentage fee on drug collections while getting expert attention on the complex claims.
What drug-billing compliance area deserves regular review?
JW and JZ modifier compliance is one drug-billing area that deserves regular review. Medicare has required JW reporting since 2017 and JZ reporting since July 2023 for applicable separately payable Part B drugs. The documentation requirements are specific, and claims missing the correct modifier may be returned unprocessed or flagged for audit. If your team is not reconciling the medication administration record against the pharmacy record and the claim for each applicable drug, you are exposed to recoupment risk regardless of whether you bill in-house or outsource.
Can an approved prior authorization still result in a denial?
Yes. The authorization must match the service actually delivered. If the dose changes, the drug is substituted, the site of care shifts, or the number of cycles exceeds what was approved, the original authorization may not cover the claim. Authorizations should be tracked at the regimen level, and any treatment change that could affect coverage should be flagged for review before the next cycle.
